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Investigation of Second Genetic Hits at the BMPR2 Locus as
a Modulator of Disease Progression in Familial Pulmonary
Arterial Hypertension
Rajiv D. Machado, PhD*; Victoria James, BSc*; Mark Southwood, BSc;
Rachel E. Harrison, MRCPCH; Carl Atkinson, PhD; Susan Stewart, FRCPath;
Nicholas W. Morrell, MD; Richard C. Trembath, FRCP; Micheala A. Aldred, DipRCPath
Background—Primary pulmonary arterial hypertension (PAH) is a potentially devastating condition resulting from
occlusion of the pulmonary arterioles by the formation of vascular lesions. Heterozygous mutations in the gene encoding
the bone morphogenetic protein receptor type II (BMPR2) have been identified in both familial (FPAH) and idiopathic
PAH. Mutant alleles are typically of low penetrance, indicating that other factors are required for the onset of PAH.
Previous reports have suggested that the characteristic plexiform lesions in affected lungs are akin to neoplasia, showing
monoclonal expansion and microsatellite instability. We hypothesized that in patients with germline mutations, BMPR2
might behave as a classic tumor suppressor gene, with somatic loss of the wild-type allele contributing to disease
progression.
Methods and Results—To test this hypothesis, plexiform and concentric vascular lesions were serially microdissected from
lung explant tissue derived from 7 FPAH cases. DNA was analyzed for loss of heterozygosity at BMPR2 and for
microsatellite instability (MSI) at 5 loci. MSI was detected in 1 of 37 lesions at a single locus, BAT-26, whereas
heterozygosity at BMPR2 was retained at all informative loci. We also describe a FPAH patient carrying biallelic
constitutional missense mutations of BMPR2 who manifested disease at a stage and manner similar to heterozygous
patients.
Conclusions—Taken together, these data demonstrate that MSI is uncommon in FPAH and suggest that somatic loss of
the remaining wild-type BMPR2 allele in heterozygous mutation carriers likely does not play a significant role in
modulating the onset or progression of FPAH. (Circulation. 2005;111:607-613.)
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Primary pulmonary arterial hypertension (PAH) is an oftenfatal condition typified by the sustained elevation of
mean pulmonary artery pressure, which leads to hypertrophy
and subsequent failure of the right heart. Histologically, the
disease is characterized by obstruction of the small pulmo-
nary arteries resulting from the development of vascular
plexiform and concentric lesions that in turn are defined by
proliferating and migrating endothelial and smooth muscle
cells.1,2 Although the majority of PAH patients spontaneously
present with disease and are regarded as idiopathic cases
(IPAH), up to 10% may have a family history of the condition
(FPAH). Inheritance of PAH is autosomal-dominant with a
sex bias to the reduced penetrance of mutant alleles.3 We and
others have demonstrated that diverse germline heterozygous
mutations in the gene encoding the bone morphogenetic
protein receptor type II (BMPR2) underlie the majority of
patients with FPAH and additionally, up to 40% of apparently
sporadically affected subjects.4–7
See p 534
BMPR-II is a type 2 receptor of the transforming growth
factor (TGF)- family of cytokines, members of which are
regarded as essential for the cellular processes of prolifera-
tion, differentiation, and apoptosis. The receptor comprises 4
functional domains (ligand binding, kinase, transmembrane,
and cytoplasmic) and relays intracellular signals in complex
with a type I receptor (BMPR-1A/1B) via the phosphoryla-
tion of a series of cytoplasmic mediators, of which the Smad
proteins are the most extensively characterized. Activated
Smads, in concert with other signaling partners, translocate to
the nucleus, where they regulate the transcription of target
genes.8 Although the Smad signaling pathway is regarded as
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a major target of TGF- signal transduction, several Smad-
independent substrates are now being elucidated, including
the mitogen-activated protein kinases (MAPKs), extracellular
signal–regulated kinase, c-Jun NH2-terminal kinase, and
p38MAPK.9
Approximately 60% of the pathogenic mutations reported
to date introduce premature truncation codons to the BMPR2
transcript, most of which are anticipated to undergo
nonsense-mediated decay, supporting haploinsufficiency of
the protein as the molecular mechanism of disease.10 By
contrast, the remainder are point mutations that occur at
functionally critical amino acid residues and have been
independently demonstrated to have heterogeneous effects on
important receptor functions, including ligand binding and
phosphorylation of substrate.11,12 In PAH kindreds, mutant
BMPR2 alleles display reduced penetrance, indicating that
heterozygous mutation of the gene is required but not
sufficient for the precipitation of disease.2 Other genetic or
environmental factors are therefore also implicated.
Two studies13,14 observed that a proportion of abnormally
proliferating endothelial cells from plexiform lesions in a
series of patients with IPAH and others who had developed
the disease secondary to the ingestion of appetite suppressant
drugs displayed monoclonal expansion. The monoclonal cell
growth within such lesions was interpreted as being akin to
neoplasia, suggesting that PAH onset necessitated somatic
mutations in genes that conferred a selective growth advan-
tage to cells.13,15 In support of this hypothesis, microsatellite
instability (MSI) and/or mutation of TGFRII or the proapo-
ptotic gene BAX was subsequently demonstrated in a propor-
tion of plexiform lesions from PAH lungs.15
Because several other genes in the TGF-/BMP superfam-
ily have known roles in neoplasia,16 we hypothesized that
FPAH and BMPR2 mutation–positive IPAH might follow the
classic “2-hit” model of tumorigenesis and that inactivation
of the remaining wild-type BMPR2 allele might be one of the
somatic mutations necessary to precipitate disease. To test
this theory, we examined microdissected pulmonary vascular
concentric and plexiform lesions from 7 FPAH cases for
evidence of somatic loss of the wild-type BMPR2 allele. We
also describe a PAH patient who showed a typical disease
course, despite harboring constitutional missense mutations
of both BMPR2 alleles.
Methods
Subjects
Patient ascertainment was performed as previously described.10 In
brief, subjects were defined as affected if pulmonary artery mean
pressure exceeded 25 mm Hg and pulmonary artery wedge
pressure was normal or if postmortem analysis identified plexo-
genic pulmonary arteriopathy.2 Subjects with FPAH were defined
by having at least 1 affected relative displaying evidence of
linkage to the BMPR2 locus. All patients were of western
European descent. Patient 1 (GER02) was of German origin with
1 affected sibling. Patient 2 (FRA01), of French origin, had an
affected parent and 3 affected siblings. Patients 3 (UK01), 4
(UK07), 5 (UK11), 6 (UK13), and 7 (UK14) were from the United
Kingdom and had 8, 1, 2, 1, and 1 affected relatives, respectively.
Germline mutations were detected among patients and carriers of
the BMPR2 disease haplotype in families of UK01, UK11, and
UK13, as previously described (Table 1).
Patient 5559, who died at the age of 20 years, was diagnosed with
PAH after cardiac catheterization revealed pulmonary artery pressure
of 154/69 mm Hg. This individual had a recorded paternal family
history of PAH but no known maternal history. Samples were not
available from either parent.
Mutation Analysis of the BMPR2 Gene
in Case 5559
DNA was isolated from peripheral blood and fresh-frozen lung
samples by standard methods. The 13 coding exons of the gene and
flanking intronic sequences were amplified by polymerase chain
reaction (PCR) with primer pairs described elsewhere.10 Both strands
of the purified PCR product were sequenced with the same primers
on an ABI377 DNA analyzer with the BigDye terminator kit. The
presence of identified mutations was excluded from a panel of 150
normal chromosomes, also by direct sequencing. To determine the
relative proportions of the 2 mutations in the compound heterozygote
patient, PCR products generated from blood and lung sources were
cloned into the PCR2.1 vector according to the manufacturer’s
instructions (Promega). Transformation into the Escherichia coli
strain DH5 was performed by the heat-shock procedure and
overnight cultures miniprepped with the Qiagen kit. A total of 70
colonies were prepared from each source, and sequencing was
carried out as described earlier.
Laser Capture Microdissection
Serial paraffin sections (10 m) were mounted on membrane-based
slides for microdissection in conjunction with 1M1000 digital
imaging software (Leica Microsystems). Immediately before micro-
dissection, sections were stained with hematoxylin and eosin to
permit identification of tissue components. At least 6 serial sections
were obtained from each patient sample, and all identified vascular
lesions were collected. Concentric and plexiform lesions were
sampled, together with random fields of normal lung parenchyma, as
detailed in Table 1. Lesions were highlighted and dissected from
tissue sections with a laser beam (0.6 m, at 32 mW, 30 Hz) and an
0.8-second pulse, as illustrated in Figure 1.
Dissected material was contained in a sterile PCR plastic collect-
ing tube cap containing 40 L of lysis buffer (TE [10 mmol/L
Tris-HCl, 1 mmol/L EDTA], pH 8.0); 1 mg/mL proteinase K; 1%
Tween-20). For DNA extraction, samples were incubated overnight
at 37°C. An additional 4 L of proteinase K (20 mg/mL) was added
TABLE 1. Details of FPAH Cases Comprising the
Microdissection Panel
Sample Mutation
No. of Lesions
Dissected
GER02 No mutation identified Plexiform 3
Concentric 2
FRA01 No mutation identified Plexiform 5
Concentric 4
UK01 5 deletion (Reference 10) Plexiform 3
Concentric 2
UK07 No mutation identified Plexiform 2
Concentric 2
UK11 1806 frameshift10 aa (Reference 10) Plexiform 2
Concentric 2
UK13 355 delA8 aa (Reference 4) Plexiform 1
Concentric 1
UK14 No mutation identified Plexiform 5
Concentric 3
del indicates deletion; aa, amino acids. All other abbreviations are as defined
in text.
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to each sample before each of 2 additional overnight incubations at
65°C. The samples were finally incubated at 95°C for 10 minutes to
inactivate the enzyme.
MSI and Loss of Heterozygosity Analysis
MSI analysis was performed with 5 microsatellite markers: BAT-25,
a thymine repeat in intron 16 of the c-kit oncogene; BAT-26, an
adenine repeat located within the fifth intron of the DNA mismatch
repair gene hMSH2; a guanine repeat in exon 3 of BAX; a 10-base
adenine repeat in exon 3 of the TGFRII gene17–20; and a 7-base
adenine repeat in BMPR2. All familial and sporadic cases were
analyzed. Primer details for these microsatellites are available on
request.
Three polymorphic markers were used to detect loss of heterozy-
gosity (LOH) at the BMPR2 locus: a previously undescribed marker
within the first intron of BMPR2; D2S3009, located in intron 12; and
D2S2289, which maps 420 kb distal of the gene. Markers used in the
MSI study were amplified with fluorescently labeled primers as
either a duplex (TGFRII and BMPR2) or a multiplex (BAT-25,
BAT-26, and BAX) PCR. Markers used in the analysis of LOH were
amplified individually. Each reaction comprised 1 Qiagen multi-
plex Mastermix, 0.2 mol/L of each primer, and 2 L of extracted
genomic DNA to a final volume of 10 L. Markers were visualized
on 6% polyacrylamide gels on an ABI 377 DNA analyzer and with
the use of GeneScan 3.0 software. PCR cycling conditions were as
follows: preincubation at 95°C for 15 minutes to activate the
polymerase; then 95°C for 30 seconds, 57°C for 90 seconds, and
72°C for 60 seconds for 40 cycles; followed by a final step of 60°C
for 30 minutes.
Results
Molecular Genetic Analysis of a Patient With
Biallelic BMPR2 Mutations
Both R491Q and K512T mutations were observed as het-
erozygous mutations in exon 11 of BMPR2 on sequencing of
DNA isolated from 2 independent sources of tissue, namely,
blood and lung. The PCR products of the exon 11 generated
from these tissues were next cloned to determine (1) whether
the mutations were in the cis or trans and (2) whether there
was evidence of a wild-type allele, which would indicate
mosaicism. Among the 140 clones analyzed, 70 from each
tissue, the 2 mutations were always detected on different
chromosomes, thus confirming the patient to be a compound
heterozygote for BMPR2 (Figure 2). Additionally, the muta-
tions were present in approximately equal proportions in both
tissues (Figure 2A) and importantly, there was no evidence of
a wild-type allele. Neither mutation was present in the control
panel of 150 normal chromosomes. Furthermore, both wild-type
amino acids at positions 491 and 512 in the BMPR-II cDNA
demonstrated evolutionary conservation across species, indicat-
ing their relevance to receptor function (Figure 2B).
Investigation of LOH at the BMPR2 Locus in
Microdissected Human Lung
A total of 37 vascular lesions (21 plexiform, 16 concentric)
were analyzed from 7 FPAH cases, and the results were
compared with normal lung parenchyma in each case.
D2S3009 was informative in all 7 cases, whereas D2S2289
and the intron 1 polymorphisms were each informative in 6
cases (Table 2). Successful PCR amplification was achieved
in 29 of 32 (91%) of informative lesions for intron 1, 35 of 37
(95%) for D2S3009, and 30 of 32 (94%) for D2S2289. In all
cases wherein genotyping was successful, heterozygosity was
retained at all informative loci (Table 2 and Figure 3).
No Evidence of MSI of 5 Genes in PAH
Human Lung
MSI analysis was conducted on the same 37 lesions, together
with normal parenchyma. Success rates for PCR amplifica-
tion ranged from 31 of 37 lesions (84%) for TGFBR2 to 36 of
37 (97%) for BAT-25 and BAX (Table 3). Aberrantly sized
fragments, indicative of microsatellite mutation, were identi-
fied in a single concentric lesion from a familial case for
marker BAT-26 and subsequently confirmed in a second
independent PCR (Figure 4). All other results were normal
(Table 3 and Figure 4).
Figure 1. Laser capture microdissection.
Representative lung sections before and
after microdissection of (A) concentric
and (B) plexiform lesions.
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Discussion
Profound MSI is a hallmark of hereditary nonpolyposis colon
carcinoma (HNPCC) and is also found in a proportion of
sporadic HNPCC-spectrum tumors, such as endometrial car-
cinoma.21 The underlying cause of MSI is a defect in
mismatch repair, which results in tumorigenesis through an
accumulation of somatic mutations in genes important for
regulating cell cycle, growth, or apoptosis. A lower level of
MSI occurs in tumors that are outside the HNPCC spectrum.
Previous studies of endothelial cells microdissected from
plexiform lesions of PAH lungs have shown monoclonal
expansion in 17 of 22 lesions (77%) from 4 patients and
microsatellite mutation rates ranging from 21% for BAX to
50% for BAT26.13,15 This suggested that endothelial cell
expansion in plexiform lesions is akin to neoplasia and might
result from an accumulation of somatic mutations, either
through MSI or other mutational mechanisms. We have now
conducted similar analyses in a series of FPAH cases in
whom BMPR2 has been fully characterized. We hypothesized
that at least in those cases with a germline BMPR2 mutation,
BMPR2 might behave as a classic tumor suppressor gene and
undergo somatic loss of the wild-type allele in pulmonary
vascular lesions, as documented for the type I receptor
BMPR1A in juvenile polyposis and Cowden syndromes.22
We performed serial microdissection of plexiform and
concentric vascular lesions and normal lung parenchyma on
paraffin-embedded lung from 7 FPAH patients. All had
previously been analyzed for a germline BMPR2 mutation by
a combination of direct sequencing, Southern blotting, and
dosage PCR, and mutations had been detected in 3 of these
cases.
Mononucleotide-repeat tracts in 5 genes were examined for
MSI, including BAT-25 and BAT-26, which are the recom-
mended diagnostic markers for HNPCC.23 Only 1 mutation
was found, in a single gene (BAT-26) in 1 concentric lesion;
no mutations were identified among 19 plexiform lesions, in
contrast with the results of Yeager et al.15 There are 2
significant differences between the 2 studies that might
account for this. First, Yeager et al15 used whole-genome
amplification (WGA) of microdissected DNA before analysis
of individual genes. In the present study, an optimized DNA
extraction protocol obviated the need for WGA. WGA can be
prone to allele dropout or other artifacts, but these were
controlled for in the previous PAH study. Thus, an alternative
explanation is that our results might represent a difference
between BMPR2 mutation-positive and mutation-negative
cases. Yeager et al studied IPAH cases, and although their
BMPR2 status was not determined, mutations have been
detected in fewer than half of IPAH patients.6,7 In the present
study, we focused on familial cases that were linked to
BMPR2, including 3 with characterized mutations. MSI is
apparently an uncommon phenomenon among this group of
patients. Similarly, we examined whether somatic LOH at the
BMPR2 locus occurred in pulmonary vascular lesions from
these patients. Heterozygosity was retained in all informative
cases for 3 markers that encompass the BMPR2 gene. These
results suggest that somatic loss of the wild-type BMPR2
allele in affected lung is not a function of disease progression
Figure 2. Mutation analysis for patient 5559. A, Pedigree repre-
sents affected individuals by filled symbols; patient 5559 is indi-
cated by star. Segments of contiguous-sequence chromato-
grams are shown, demonstrating 2 different heterozygous alleles
identified in this subject. Double diagonal line represents inter-
vening 60 bases, omitted for clarity. Allele 1 has G3A transition
at codon 491 and is wild type at codon 512, whereas allele 2 is
wild type at codon 491 and shows A3C transversion at codon
512. Allele frequencies were obtained by sequencing 70 clones
from each of lung- and blood-derived DNA. B, BMPR-II
sequence from amino acids 487 to 516 demonstrating conser-
vation of residues 491 and 512, shown in red, across species.
TABLE 2. Summary of Results From LOH Analysis
Sample Intron 1 D2S3009 D2S2289
GER02 P0/3 P0/3 Uninformative
C0/2 C0/1
FRA01 P0/5 P0/5 P0/5
C0/4 C0/4 C0/2
UK01 Uninformative P0/3 P0/3
C0/2 C0/2
UK07 P0/2 P0/2 P0/2
C0/2 C0/2 C0/2
UK11 P0/2 P0/2 P0/2
C0/2 C0/2 C0/2
UK13 P0/1 P0/1 P0/1
C0/1 C0/1 C0/1
UK14 P0/4 P0/4 P0/5
C0/1 C0/3 C0/3
P indicates plexiform; C, concentric. All other abbreviations are as defined in
text. Results are expressed as number of samples displaying LOH of the total
number that were successfully amplified.
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in FPAH. However, we have previously noted an almost-
complete absence of BMPR-II protein in FPAH lung on
immunohistochemistry.24 Thus other “second hits,” such as
somatic mutation, hypermethylation of the BMPR2 promoter,
or other factors secondary to perturbation of upstream regu-
latory proteins, remain possible mechanisms.
The BMPR2 gene has been knocked out in the mouse by 2
independent groups in an effort to assess its importance in
early development. As reported by Beppu et al,25 although
heterozygous mice harboring an ablated BMPR2 allele appear
phenotypically normal, mutant homozygotes die in utero at
gastrulation. A second homozygous mutant of BMPR2, gen-
erated by the inframe deletion of exon 2, survived longer than
the knockout model but was nevertheless lethal during
embryogenesis.26 These findings strongly argue that at least 1
functional BMPR2 allele is necessary for survival, therefore
raising the question of how the biallelic germline pathogenic
mutation in the patient we describe herein was compatible
with normal development and survival until adulthood.
The R491Q mutation has been described in other PAH
families5 and is thus, clearly pathogenic. K512T has not
previously been reported in PAH cases. However, this muta-
tion was not detected among 150 control chromosomes.
Furthermore, this mutation has previously been characterized
functionally and was shown to perturb BMPR-II signaling.11
It is therefore unlikely to be an innocuous polymorphism. A
second possible explanation is that 1 of the 2 mutations arose
postzygotically, and the patient might be a mosaic, with a
sufficient proportion of wild-type alleles to rescue develop-
ment. The patient’s father was also affected with PAH, and
thus, 1 mutation is presumed to be paternally inherited.
Parental DNA samples were not available, and thus, it is not
possible to determine whether the second mutation was
inherited from the unaffected mother. However, no wild-type
alleles were detected among 70 clones analyzed from each of
blood and lung-derived DNA. This argues strongly against
mosaicism resulting from a late-postzygotic mutation and
suggests that patient 5559 is constitutionally compound
heterozygous for 2 different BMPR2 mutations.
Both of these missense mutations have been extensively
characterized, and although both clearly perturb the BMPR-II
signaling pathway, their effects are subtly distinct biochem-
ically. The kinase p38MAPK is normally a downstream target of
BMPR-II after activation of the receptor by ligand. However,
both mutant receptors elevate the phosphorylation of this
substrate constitutively, with the K512T mutation stimulating
this effect to a significantly greater degree than R491Q.
Perhaps the most critical distinction between these 2 muta-
tions lies in their respective effects on activation of the Smad
pathway. In luciferase reporter assays, the kinase domain
mutation R491Q leads to a reduction of activation of the
reporter to below endogenous levels, consistent with a
Figure 3. Heterozygosity at BMPR2
locus is retained in FPAH lungs. Repre-
sentative results are shown: D2S3009 in
GER02, concentric (A and B) and plexi-
form (C, D, and E) lesions and normal
lung (F); intron 1 in UK13, concentric (G)
and plexiform lesions (H) and normal
lung (I); and D2S2289 in UK14, concen-
tric (J) and plexiform lesions (K) and nor-
mal lung (L).
TABLE 3. Summary of Results From MSI Analysis
Sample BAT-25 (c-Kit) BAT-26 (MSH2) Bax TGF-2 BMPR2
GER02 P0/3 P0/3 P0/3 P0/2 P0/2
C0/2 C0/2 C0/2 C0/2 C0/2
FRA01 P0/5 P0/5 P0/5 P0/5 P0/5
C0/4 C1/3 C0/4 C0/4 C0/4
UK01 P0/2 P0/2 P0/2 P0/2 P0/2
C0/2 C0/2 C0/2 C0/2 C0/2
UK07 P0/2 P0/2 P0/2 P0/1 P0/2
C0/2 C0/2 C0/2 C0/2 C0/2
UK11 P0/2 P0/2 P0/2 P0/2 P0/2
C0/2 C0/2 C0/2 C0/2 C0/2
UK13 P0/1 P0/1 P0/1 P0/1 P0/1
C0/1 C0/1 C0/1 C0/1 C0/1
UK14 P0/5 P0/5 P0/5 P0/3 P0/3
C0/3 C0/3 C0/3 C0/2 C0/2
All abbreviations are as defined in text or in the footnote to Table 2. Results
are expressed as number of samples displaying MSI of the total number that
were successfully amplified.
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dominant-negative effect on Smad signaling. In contrast,
K512T reduced reporter gene activity by comparison with
cells transfected with the wild-type receptor but did not
compromise endogenous signaling activity.11 We therefore
propose that K512T is a pathogenic mutation that impairs
BMPR-II signaling activity but retains sufficient residual
Smad activity to permit normal embryonic development in
the compound-heterozygote patient. The observation that
despite apparently minimal BMPR-II activity, her age at PAH
diagnosis and subsequent disease progression were compara-
ble to those in individuals with heterozygous BMPR2 muta-
tions, and this suggests that further perturbation of BMPR-II
signaling in heterozygous carriers is not a significant factor in
the precipitation or progression of FPAH.
In conclusion, we have examined microdissected pulmo-
nary vascular lesions from a series of FPAH patients. MSI
was uncommon, being found in only 1 of 37 lesions for a
single mononucleotide repeat. Furthermore, no evidence for
LOH was found at the BMPR2 locus. We have also investi-
gated a patient with compound heterozygosity for 2 distinct
BMPR2 mutations. Surprisingly, the course of the disease in
this patient was not dissimilar to the typical presentation and
progression of PAH. Taken together, these 2 seemingly
disparate sets of data suggest that somatic loss of wild-type
BMPR2 alleles or mutation of proapoptotic genes is unlikely
to play a significant role in the pathogenesis of FPAH. The
identification of other genetic or environmental factors that
modulate the onset and progression of this disease remains an
important priority.
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